NAD as a genotype-specific drug target

Szu Chieh Mei; Charles Brenner

doi:10.1016/j.chembiol.2013.11.001

NAD as a genotype-specific drug target

Szu Chieh Mei, Charles Brenner

Research output: Contribution to journal › Short survey › peer-review

7 Scopus citations

Abstract

Using high-throughput chemical and genetic screening, Matheny and colleagues (in this issue of Chemistry & Biology) identified STF-118804, an inhibitor of nicotinamide phosphoribosyltransferase, as a cell type-specific inhibitor of mixed-lineage leukemia with MLL chromosomal rearrangements. The approach was powerful, as is the potential for NAD as a specific cancer target.

Original language	English (US)
Pages (from-to)	1307-1308
Number of pages	2
Journal	Chemistry and Biology
Volume	20
Issue number	11
DOIs	https://doi.org/10.1016/j.chembiol.2013.11.001
State	Published - Nov 21 2013
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Molecular Biology
Pharmacology
Drug Discovery
Clinical Biochemistry

Access to Document

10.1016/j.chembiol.2013.11.001

Cite this

@article{3ef03b6ef8f843499fbcf5eb07ea6518,

title = "NAD as a genotype-specific drug target",

abstract = "Using high-throughput chemical and genetic screening, Matheny and colleagues (in this issue of Chemistry & Biology) identified STF-118804, an inhibitor of nicotinamide phosphoribosyltransferase, as a cell type-specific inhibitor of mixed-lineage leukemia with MLL chromosomal rearrangements. The approach was powerful, as is the potential for NAD as a specific cancer target.",

author = "Mei, {Szu Chieh} and Charles Brenner",

year = "2013",

month = nov,

day = "21",

doi = "10.1016/j.chembiol.2013.11.001",

language = "English (US)",

volume = "20",

pages = "1307--1308",

journal = "Chemistry and Biology",

issn = "1074-5521",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - NAD as a genotype-specific drug target

AU - Mei, Szu Chieh

AU - Brenner, Charles

PY - 2013/11/21

Y1 - 2013/11/21

N2 - Using high-throughput chemical and genetic screening, Matheny and colleagues (in this issue of Chemistry & Biology) identified STF-118804, an inhibitor of nicotinamide phosphoribosyltransferase, as a cell type-specific inhibitor of mixed-lineage leukemia with MLL chromosomal rearrangements. The approach was powerful, as is the potential for NAD as a specific cancer target.

AB - Using high-throughput chemical and genetic screening, Matheny and colleagues (in this issue of Chemistry & Biology) identified STF-118804, an inhibitor of nicotinamide phosphoribosyltransferase, as a cell type-specific inhibitor of mixed-lineage leukemia with MLL chromosomal rearrangements. The approach was powerful, as is the potential for NAD as a specific cancer target.

UR - http://www.scopus.com/inward/record.url?scp=84888256566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888256566&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2013.11.001

DO - 10.1016/j.chembiol.2013.11.001

M3 - Short survey

C2 - 24267273

AN - SCOPUS:84888256566

SN - 1074-5521

VL - 20

SP - 1307

EP - 1308

JO - Chemistry and Biology

JF - Chemistry and Biology

IS - 11

ER -

NAD as a genotype-specific drug target

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this